The Paediatric Neurosciences Research Group, Royal Hospital for Sick Children, Yorkhill, Dalnair Street, Glasgow G3 8SJ, UK.
Brain. 2012 Aug;135(Pt 8):2329-36. doi: 10.1093/brain/aws151. Epub 2012 Jun 19.
Dravet syndrome is a severe infantile onset epileptic encephalopathy associated with mutations in the sodium channel alpha 1 subunit gene SCN1A. To date no large studies have systematically examined the prognostic, clinical and demographic features of the disease. We prospectively collected data on a UK cohort of individuals with Dravet syndrome during a 5-year study period and analysed demographic information based on UK population and birth figures. From structured referral data we examined a range of clinical characteristics including epilepsy phenotype, seizure precipitants, electroencephalography data, imaging studies, mutation class and response to medication. Predictors of developmental outcome were determined by logistic regression. We identified 241 cases with SCN1A mutation-positive Dravet syndrome, 207 of which were UK-based. The incidence of mutation-positive Dravet syndrome is at least 1:40 900 UK births. Clinical features predicting a worse developmental outcome included status epilepticus (odds ratio = 3.1; confidence interval = 1.5-6.3; P = 0.003), interictal electroencephalography abnormalities in the first year of life (odds ratio = 5.7; confidence interval = 1.9-16.8; P = 0.002) and motor disorder (odds ratio = 3.3; confidence interval = 1.7-6.4; P < 0.001). No significant effect was seen for seizure precipitants, magnetic resonance imaging abnormalities or mutation class (truncating versus missense). Abnormal magnetic resonance imaging was documented in 11% of cases, principally with findings of non-specific brain atrophy or hippocampal changes. Sodium valproate, benzodiazepines and topiramate were reported as being the most helpful medications at the time of referral. Aggravation of seizures was reported for carbamazepine and lamotrigine. The identification of factors influencing prognosis both aids counselling and encourages early, syndrome-specific therapy. Prevention of status epilepticus with regular medication and emergency protocols is important and may influence developmental outcome.
德拉维特综合征是一种严重的婴儿期起病的癫痫性脑病,与钠离子通道α 1 亚单位基因 SCN1A 的突变有关。迄今为止,尚无大型研究系统地检查过该疾病的预后、临床和人口统计学特征。我们在 5 年的研究期间前瞻性地收集了英国德拉维特综合征患者的队列数据,并根据英国人口和出生数据分析了人口统计学信息。根据结构化转诊数据,我们检查了一系列临床特征,包括癫痫表型、癫痫发作诱因、脑电图数据、影像学研究、突变类型和对药物的反应。通过逻辑回归确定了发育结果的预测因子。我们确定了 241 例 SCN1A 突变阳性的德拉维特综合征患者,其中 207 例来自英国。突变阳性的德拉维特综合征的发病率至少为每 40900 例英国出生 1 例。预测发育结果较差的临床特征包括癫痫持续状态(优势比=3.1;置信区间=1.5-6.3;P=0.003)、生命第一年的间期脑电图异常(优势比=5.7;置信区间=1.9-16.8;P=0.002)和运动障碍(优势比=3.3;置信区间=1.7-6.4;P<0.001)。癫痫发作诱因、磁共振成像异常或突变类型(截断与错义)均无显著影响。11%的病例记录到异常磁共振成像,主要为非特异性脑萎缩或海马变化。在转诊时,报告了钠缬草氨酸、苯二氮䓬类和托吡酯是最有帮助的药物。卡马西平和拉莫三嗪的报告加重了癫痫发作。确定影响预后的因素既有助于咨询,又鼓励早期、综合征特异性治疗。通过定期用药和紧急方案预防癫痫持续状态很重要,可能会影响发育结果。